Trial Profile
Anlotinib Hydrochloride as second-line therapy in elderly patients with EGFR wild-type lung adenocarcinoma who refused chemotherapy: an open, single-arm, single-center clinical trial
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Aug 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 14 Aug 2018 New trial record